# Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))

> **NCT01163292** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 220 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01163292
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2018-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163292, "Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01163292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*